What if AI could help clinicians move beyond detection and make breast cancer treatment more precise and personalized?

In this episode of Entrepreneur Rx, host John Shufeldt sits down with Stacey Stevens, CEO of SimBioSys, to discuss her career in medical technology, healthcare AI, women’s health, and precision oncology. Stacey shares how her experience at Philips Healthcare, iCAD, and her own women’s health advisory company shaped her path to leading SimBioSys.

The conversation explores Stacey’s early work helping bring some of the first AI tools in breast imaging to market, the long road to healthcare adoption, and why clinical evidence, trust, reimbursement, and enterprise-grade security all matter when selling AI into healthcare.

Stacey also explains how SimBioSys is taking AI beyond breast cancer detection and applying it to treatment planning. The company’s platform uses breast MRI data to create interactive 3D visual models of the breast and tumor, helping surgical oncologists better understand tumor location, volume, and whether a patient may be eligible for breast-conserving surgery.

John and Stacey also discuss SimBioSys’ next frontier: using image-based AI to help assess a patient’s risk of breast cancer recurrence and support more personalized treatment decisions. Beyond the technology, the episode covers startup leadership, fundraising, the realities of building in regulated healthcare, and why trust, transparency, and patient impact must come first.

About Stacey Stevens: Stacey Stevens is the CEO of SimBioSys and a healthcare technology executive with deep experience in medical imaging, AI, women’s health, commercialization, fundraising, and strategic growth. Before joining SimBioSys, she held leadership roles at Philips Healthcare and iCAD, where she helped introduce early AI technologies in breast imaging. She also founded Ellevate, a women’s health strategic advisory company focused on accelerating the adoption of meaningful scientific breakthroughs in women’s health.

About SimBioSys: SimBioSys is developing a precision medicine platform initially focused on breast cancer, with technology designed to support clinicians and patients across the cancer care journey. Its platform uses AI and spatial biophysics to turn breast MRI data into interactive 3D visual models that can support surgical planning, treatment decisions, and more personalized cancer care.

About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund ($5,000 minimum interval fund), the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. Its portfolio includes companies developing solutions that have the potential to transform industries and improve lives.